Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Cash from Operations (2016 - 2020)

Alterity Therapeutics has reported Cash from Operations over the past 3 years, most recently at 5180869.14 for Q4 2018.

  • For Q4 2018, Cash from Operations fell 474.49% year-over-year to 5180869.14; the TTM value through Dec 2018 reached 10535879.26, up 6.87%, while the annual FY2025 figure was 7421889.44, 10.23% up from the prior year.
  • Cash from Operations for Q4 2018 was 5180869.14 at Alterity Therapeutics, down from 47278.38 in the prior quarter.
  • Over five years, Cash from Operations peaked at 47278.38 in Q2 2018 and troughed at 5539431.28 in Q2 2016.
  • A 3-year average of 2756853.94 and a median of 2653865.87 in 2017 define the central range for Cash from Operations.
  • On a YoY basis, Cash from Operations climbed as much as 98.93% in 2018 and fell as far as 474.49% in 2018.
  • Year by year, Cash from Operations stood at 465813.11 in 2016, then tumbled by 93.6% to 901823.06 in 2017, then crashed by 474.49% to 5180869.14 in 2018.
  • Business Quant data shows Cash from Operations for ATHE at 5180869.14 in Q4 2018, 47278.38 in Q2 2018, and 901823.06 in Q4 2017.